DBV Fundamental Analysis - DBV TECHNOLOGIES SA

Fundamental Rating

Taking everything into account, DBV scores 3 out of 10 in our fundamental rating. DBV was compared to 86 industry peers in the Biotechnology industry. DBV has a bad profitability rating. Also its financial health evaluation is rather negative. DBV is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

DBV had negative earnings in the past year.
DBV had a negative operating cash flow in the past year.
In the past 5 years DBV always reported negative net income.
DBV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -85.56%, DBV is not doing good in the industry: 73.26% of the companies in the same industry are doing better.
The Return On Equity of DBV (-142.22%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROIC	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 91.34%, DBV belongs to the top of the industry, outperforming 88.37% of the companies in the same industry.
DBV's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for DBV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DBV has more shares outstanding
Compared to 5 years ago, DBV has more shares outstanding
Compared to 1 year ago, DBV has a worse debt to assets ratio.

2.2 Solvency

DBV has an Altman-Z score of -2.18. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
DBV has a worse Altman-Z score (-2.18) than 66.28% of its industry peers.
DBV has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of DBV (0.08) is better than 69.77% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-2.18

ROIC/WACCN/A

WACC7.98%

2.3 Liquidity

A Current Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.
DBV has a Current ratio of 2.45. This is comparable to the rest of the industry: DBV outperforms 53.49% of its industry peers.
DBV has a Quick Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.45, DBV is doing good in the industry, outperforming 60.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.45
Quick Ratio	2.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DBV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.
The Revenue has grown by 224.69% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 0.50% on average over the past years.

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

3.2 Future

DBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.
Based on estimates for the next years, DBV will show a very strong growth in Revenue. The Revenue will grow by 75.93% on average per year.

EPS Next Y-36.93%

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

EPS Next 5Y16.26%

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

DBV's earnings are expected to grow with 40.68% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DBV!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

DBV TECHNOLOGIES SA

FRA:DBV (1/19/2026, 7:00:00 PM)

3.505

+0.42 (+13.8%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/amc

Earnings (Next)03-23 2026-03-23/amc

Inst Owners69.74%

Inst Owner ChangeN/A

Ins Owners0.1%

Ins Owner ChangeN/A

Market Cap126.00M

Revenue(TTM)15.73M

Net Income(TTM)-122.55M

Analysts80

Price Target4.02 (14.69%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)N/A

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)22.46%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	38.52
P/FCF	N/A
P/OCF	N/A
P/B	1.7
P/tB	1.7
EV/EBITDA	N/A

EPS(TTM)-0.65

EYN/A

EPS(NY)-0.68

Fwd EYN/A

FCF(TTM)-2.11

FCFYN/A

OCF(TTM)-2.1

OCFYN/A

SpS0.09

BVpS2.06

TBVpS2.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.34%
FCFM	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.61%
Cap/Sales	8.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.45
Quick Ratio	2.45
Altman-Z	-2.18

F-Score2

WACC7.98%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)25.42%

Cap/Sales(5y)23.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y-36.93%

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

EPS Next 5Y16.26%

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

EBIT growth 1Y-31.77%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-9.76%

EBIT Next 3Y32.47%

EBIT Next 5YN/A

FCF growth 1Y0.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.02%

OCF growth 3YN/A

OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.DE FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 3 / 10 to DBV.DE.

What is the valuation status of DBV TECHNOLOGIES SA (DBV.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.DE). This can be considered as Overvalued.

Can you provide the profitability details for DBV TECHNOLOGIES SA?

DBV TECHNOLOGIES SA (DBV.DE) has a profitability rating of 1 / 10.

Can you provide the financial health for DBV stock?

The financial health rating of DBV TECHNOLOGIES SA (DBV.DE) is 3 / 10.

DBV TECHNOLOGIES SA (DBV.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DBV TECHNOLOGIES SA / DBV.DE FAQ

What is the fundamental rating for DBV stock?

What is the valuation status of DBV TECHNOLOGIES SA (DBV.DE) stock?

Can you provide the profitability details for DBV TECHNOLOGIES SA?

Can you provide the financial health for DBV stock?